Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To compare tumor necrosis factor alpha inhibitors directly regarding the rates of
treatment response, remission, and the drug survival rate in patients with rheumatoid
arthritis (RA), and to identify clinical prognostic factors for response.